{
    "clinical_study": {
        "@rank": "46726", 
        "arm_group": [
            {
                "arm_group_label": "Methyldopa", 
                "arm_group_type": "Experimental", 
                "description": "In case group, 25 patients, under treatment, using Methyldopa for 7 days, received 500 mgs of Methyldopa in its oral form per day and in control group, participants received placebo for 7 days."
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The present study examined the effects of Methyldopa on uterine artery diameter, uterine\n      artery blood flow, umbilical artery and fetal middle-cerebral artery in patients with\n      Preeclampsia, using Doppler ultrasound."
        }, 
        "brief_title": "Effect of Methyldopa on Uterine Artery Diameter in Pregnant Women With Mild Preeclampsia", 
        "completion_date": {
            "#text": "May 2012", 
            "@type": "Actual"
        }, 
        "condition": "Pregnant Women With Mild Preeclampsia", 
        "condition_browse": {
            "mesh_term": "Pre-Eclampsia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "They met the inclusion criteria, If they had over 25 weeks of gestational age, no history\n        of chronic hypertension, no diabetes mellitus, no chronic systemic diseases, no collagen\n        vascular diseases and antiphospholipid syndromes, no use of antihypertensive drugs and BMI\n        higher than 19 and lower than 30 (kg/m2)."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01674127", 
            "org_study_id": "390306"
        }, 
        "intervention": [
            {
                "arm_group_label": "Methyldopa", 
                "intervention_name": "Methyldopa", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Methyldopa"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 27, 2012", 
        "number_of_arms": "2", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Iran: Ministry of Health"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "In case group, 25 patients, under treatment, using Methyldopa for 7 days, received 500 mgs of Methyldopa in its oral form per day and in control group, participants received placebo for 7 days.Before and after drug use, Doppler ultrasound test was done by a radiology specialist not informed of patients grouping. Also, pulsatility index, resistance index, systolic/diastolic blood flow ratios of uterine artery, umbilical artery and middle-cerebral artery were evaluated. Registered for all patients, age, BMI, gestational week and the number of pregnancies were among other examined variables.\nDoppler indices of examined arteries in studied groups were evaluated by color Doppler ultrasound of model \"Hitachi 3/6 MHz\".", 
            "measure": "Doppler indices", 
            "safety_issue": "Yes", 
            "time_frame": "7 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01674127"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Isfahan University of Medical Sciences", 
            "investigator_full_name": "Mojtaba Akbari", 
            "investigator_title": "...", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Isfahan University of Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Isfahan University of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}